Agreement with Medca Japan extends network of CAP-certified laboratories
RESEARCH TRIANGLE PARK, N.C., March 26 /PRNewswire/ -- Quintiles
Transnational Corp. today announced an agreement with Medca Japan to
provide central laboratory services, further extending the Quintiles global
network of laboratories certified by the College of American Pathologists
(CAP).
Quintiles will have its own staff at the CAP-certified Medca Japan
laboratory in Saitama, a city in the Greater Tokyo area. The lab will
support clinical trials in Japan.
"Recent changes in legislation are allowing Japanese pharmaceutical
companies to extend clinical trials normally conducted in Japan to other
countries in Asia, but these companies have had difficulty finding central
lab services that are harmonized throughout the region," said Tom Wollman,
Senior Vice President, Quintiles Global Central Laboratories. "With
CAP-certified labs in Beijing, Singapore, Mumbai and now Japan, we can
provide well- controlled processes and harmonized testing services
throughout the Asia- Pacific region to customers in Japan as well as our
multinational customers. This lab, along with all labs in our network, will
follow the same standard operating procedures, and data will be available
on our QNET database."
"We have established excellent systems for providing high-quality
central laboratory services based on Quintiles' global standard," said Yoh
Narimatsu, President, Quintiles Transnational Japan K.K., a subsidiary of
Quintiles Transnational. "We are determined to continue to increase
clinical trials in Japan and provide superior services for our customers
through this strategic business alliance."
Yutaka Kannari, president of Medca Japan Laboratory Co., Ltd., said he
was pleased that Medca has the capability and the high quality standards
necessary to play an important role in the expansion of Quintiles' business
in Asia, and he also sees the alliance helping Medca.
"This collaboration with Quintiles will be very helpful for the future
success of Medca Japan," he said. "We receive more than 30,000 specimens
for examination per day, and this relationship will allow us to strengthen
out clinical trial services while supporting continued growth of our
existing laboratory operations."
Medca provides a broad range of laboratory services, including
biochemical tests as well as endocrine testing, tumor marker testing,
drug-level testing, immunology testing and microbiological testing. The
laboratory has undertaken specimens for examination from about 4,000
medical institutions throughout Japan.
The relationship with Medca will be managed within Quintiles by Alan
Ong, Vice President and General Manager, Quintiles Labs Asia, who will give
technical guidance, and Narimatsu, who will provide his expertise on the
Japan market.
CAP certification follows a site inspection. The accreditation is
intended to improve patient safety by advancing the quality of pathology
and laboratory services through education, setting standards and ensuring
laboratories meet or exceed regulatory requirements.
About Quintiles Laboratories
Quintiles Laboratories owns a CAP-certified network of clinically
harmonized facilities in the U.S., Europe, South Africa, India, China and
Singapore, and has a tightly controlled network of sub-contractor
laboratories in Argentina, Brazil and Japan managed by Quintiles employees
located in each of the sub-contractor facilities.
About Quintiles Transnational Japan K.K.
Quintiles Transnational Japan K.K. is the Japanese subsidiary of
Quintiles Transnational Corp. It is the largest contract pharmaceutical
organization (CPO) in Japan to provide total solutions such as strategic
marketing services and consultation. Quintiles Japan offers services from
the Clinical Development Division, the commercialization division Innovex
and NovaQuest, Quintiles' strategic investment and partnering group. For
further information, please visit the company's website at
http://www.quintiles.co.jp.
About Quintiles
Quintiles Transnational Corp. is powering the next generation of
healthcare by providing a broad range of professional services in drug
development, financial partnering and commercialization for the
pharmaceutical, biotechnology and healthcare industries. With more than
19,000 employees and offices in more than 50 countries, it is focused on
providing customer-centric solutions that are the gold standard of the
industry. For more information, please visit the company's Web site at
http://www.quintiles.com.
SOURCE Quintiles Transnational Corp.
 back to top
Related links:
http://www.quintiles.com
http://www.quintiles.co.jp
CONTACT:
Dick Jones, Media Relations,
media.info@quintiles.com, +1-919-998-2091, or Greg Connors,
Investor Relations, invest@quintiles.com, +1-919-998-2000
|
